Syros tyme technologies
WebJul 5, 2024 · In the merger, Syros expects to issue approximately 74.3 million shares of its common stock to TYME stockholders to acquire TYME’s expected net cash at closing and … WebSep 15, 2024 · Syros Pharmaceuticals, Inc. SYRS, a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. TYME today announced the results of the special ...
Syros tyme technologies
Did you know?
WebSep 15, 2024 · Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. WebSep 15, 2024 · CAMBRIDGE, Mass. & BEDMINSTER, N.J., September 15, 2024--Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme ...
WebTYME is an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™) that are intended to be effective across a broad range of solid tumors and hematologic cancers, while also maintaining patients’ quality of life through relatively low toxicity profiles. WebNov 14, 2024 · In September, Syros announced the closing of its merger with TYME Technologies, pursuant to which Syros acquired TYME, including its pipeline assets and net cash at closing of approximately $60 million. Concurrent with the closing of the merger, Syros also closed the previously announced oversubscribed $130 million private …
WebJul 5, 2024 · (RTTNews) - Syros Pharmaceuticals (SYRS) and TYME Technologies, Inc. (TYME) announced that the companies have entered into a definitive merger agreement … WebJul 5, 2024 · Syros Merges with TYME Technologies, Raises $190 Million in a PIPE Offering July 5, 2024 Syros Pharmaceuticals, a company focused on the development of medicines that control the expression of genes will acquire Tyme Technologies, a company developing cancer metabolism-based therapies with low toxicity profiles.
WebSyros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are …
WebApr 10, 2024 · Syros Announces Closing of Merger with Tyme Technologies and Concurrent Private Placement CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, Inc. … marlboro ma extended weather forecastWebJul 5, 2024 · Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros … nba 2k22 realistic sliders ps4WebJul 5, 2024 · Per the terms, Syros ( SYRS) will issue ~74.3M shares of its common stock to TYME investors, and TYME stockholders are entitled to nearly 0.4312 shares of Syros ( SYRS) common stock for... marlboro lunch bagWebJul 5, 2024 · Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement Combined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data nba 2k22 players to trade forWebJun 28, 2024 · TYME (Nasdaq: TYME), an innovative biotechnology company leveraging novel and data-driven approaches to develop therapeutics for difficult to treat cancers. Science & Technology Bedminster, NJ 07921 tymeinc.com Joined June 2024. 1,200 Following. 1,157 Followers. marlboro ma 15 day weather forecastWebSep 15, 2024 · TYME Tyme Technologies Inc New Syros and Tyme Technologies Announce Stockholder Approval of Merger -- Combined Company to Trade on Nasdaq Under Ticker 'SYRS' ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2024 (GLOBE NEWSWIRE... nba 2k22 ps4 discount codeWebAug 9, 2024 · CAMBRIDGE, Mass.-- (BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2024 and provided a corporate update. nba 2k22 price xbox one